The sole purpose of this action was to prevent the sale of generic versions and of parallel imports of the capsule formulation 499 The EGC upheld an earlier decision by the EU Commission, considering that the withdrawal of regulatory approval for the capsule version of the drug constituted an abuse of the company’s dominant position in the market for anti-ulcer treatments. The EGC stressed that, while a dominant undertaking is under no obligation to protect the interests of competitors, this cannot “justify recourse to practices falling outside the scope of competition on the merits. The withdrawal would not have been abusive if there had been some objective reason why such a withdrawal was necessary to improve the competitiveness of the company’s own products.